Business
ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology
Intellectual Property Portfolio Now Stands at 71 Globally Issued Patents ANN ARBOR, Mich.--(BUSINESS WIRE)-- ENDRA Life Sciences Inc. (NASDAQ: NDRA), a
About this update from Endra Life Sciences Inc.
[{"type":"text","content":"\nIntellectual Property Portfolio Now Stands at 71 Globally Issued Patents\n\n\n ANN ARBOR, Mich.--(BUSINESS WIRE)--\nENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued to ENDRA a new patent, U.S. Patent No. 11828727 (the ‘727 patent) titled “Thermoacoustic Probe.”\n\n\nThe ‘727 patent relates to a thermoacoustic probe design with an optical transducer and an integrated wedge, which helps to minimize unwanted signals and optimizes radiofrequency signals to the targeted regions of interest. The '727 patent builds upon ENDRA’s U.S. Patent No. 11730374, and is the second of two structural embodiments that ENDRA is patenting to further protect its core technology.\n\n\n“We are pleased with our continued IP momentum as TAEUS’ De Novo request advances through regulatory review. This 39th U.S. patent bolsters our thermoacoustic technology in areas of high unmet clinical need,” stated ENDRA’s Chairman and Chief Executive Officer Francois Michelon. “With a total of 71 patents granted worldwide, ENDRA possesses robust IP protection for its novel TAEUS’ technology in key global markets.”\n\n\nAbout ENDRA Life Sciences Inc.\n\n\nENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology, which characterizes tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with over 700,000 ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Steatotic Liver Disease (SLD) (formerly known as NAFLD-NASH), a chronic liver spectrum that affects over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.\n\n\nForward-Looking Statements\n\n\nAll statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, wh...